Oskar Adolfsson

USPTO Granted Patents = 17 (Patent Applications = 2)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 53(Granted Patents)

Location History:

Lausanne, CH (2022)
Bercher, CH (2015 - 2023)

Company Filing History:

Katholieke Universiteit Leuven

patents

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11555065 - Anti-Tau antibodies and methods of use (2023-01-17),

2. 11466077 - Misfolded TDP-43 binding molecules (2022-10-11),

3. 11427629 - Anti-Tau antibodies and methods of use (2022-08-30),

4. 11352419 - Anti-tau antibodies and methods of use (2022-06-07),

5. 10836817 - Anti-Tau antibodies and methods of use (2020-11-17),

6. 10711058 - Anti-Tau antibodies and methods of use (2020-07-14),

7. 10633436 - Anti-tau antibodies and methods of use (2020-04-28),

8. 10336819 - Anti-Tau antibodies and methods of use (2019-07-02),

9. 10329344 - Anti-Tau Antibodies and methods of use (2019-06-25),

10. 10112990 - Anti-Tau antibodies and methods of use (2018-10-30),

11. 10100104 - Methods of diagnosing tau-protein-associated disease (2018-10-16),

12. 10066010 - Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising Tau (2018-09-04),

13. 9657091 - Humanized tau antibody (2017-05-23),

14. 9598485 - Anti-tau antibodies and methods of use (2017-03-21),

15. 9540434 - Phosphospecific antibodies recognising tau (2017-01-10),

Title: Oskar Adolfsson: Innovator in Biotech and Neurological Research

Introduction

Oskar Adolfsson, based in Bercher, Switzerland, is a notable inventor with a significant portfolio of innovations, boasting 17 patents to his name. His research primarily focuses on the development of novel therapeutic approaches for neurological disorders, which have profound implications for healthcare and patient treatment.

Latest Patents

Adolfsson's latest inventions include groundbreaking advancements such as the production of anti-Tau antibodies and methods of their use. This invention focuses on therapeutic strategies targeting Tau pathology, which is critical in neurodegenerative diseases. Additionally, he has developed misfolded TDP-43 binding molecules, which are pivotal in diagnosing and treating disorders associated with TDP-43 misfolding, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD). His contributions provide essential tools for diagnosing, preventing, and treating TDP-43-related conditions, paving the way for advancements in medical science.

Career Highlights

Throughout his career, Adolfsson has made significant strides in biotechnology and pharmaceuticals. He has worked with reputable organizations such as AC Immune SA and Genentech, Inc., which highlights his expertise and the trust placed in his innovative capabilities. His work is defined by a commitment to developing solutions for complex neurological disorders.

Collaborations

Oskar Adolfsson has collaborated with esteemed colleagues like Andreas Muhs and Isidro Hotzel, fostering an environment of innovation and shared knowledge. These collaborations have enhanced his research outcomes and contributed to the broader field of neurological studies through pooled resources and expertise.

Conclusion

Oskar Adolfsson's contributions to the field of biotechnology exemplify the importance of innovation in addressing critical healthcare challenges. With his extensive patent portfolio and collaborative efforts, he continues to be a key figure in advancing treatment options for neurological disorders. His work stands as a testament to the impact of dedicated researchers and inventors in the pursuit of better healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.